CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead
List Price: US $925
Delivery format: Electronic PDF delivery within one business day upon payment.
*This report is included at no extra cost for STRATEGIC ADVANTAGE clients, and is accessible in the Trend Reports section here. Learn more about PharmSource STRATEGIC ADVANTAGE outsourcing intelligence portal.
Emerging bio/pharmaceutical companies are benefiting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to grow but at a modest rate.
According to the latest PharmSource Trend Report, CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead, the impact of this increased funding is only just being felt. The report analyzes the factors that drive bio/pharmaceutical development spending and the demand for contract development services.
Who should buy this report?
This 9-page report provides important insight that you won’t find in any other source. It is required reading for:
- CRO, CMO and CDMO executives and others with a strategic interest in bio/pharmaceutical outsourcing.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Published November 2014